Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trials

Panelists discuss recent updates in the management of relapsed/refractory multiple myeloma, focusing on key studies such as MonumenTAL-2 for talquetamab, long-term follow-up data from the phase 1/2 MajesTEC-1 for teclistamab, and findings from MagnetisMM-3 regarding elranatamab.

EP: 1.Current Landscape of Relapsed/ Refractory Multiple Myeloma

Now Viewing

EP: 2.Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trials

EP: 3.Bispecifics in Relapsed/ Refractory Multiple Myeloma: Combination Strategies, Stepping Up, and Treatment Dose Considerations

EP: 4.Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma

EP: 5.Strategies for Community Adoption of Bispecifics into Treatment of Relapsed/ Refractory Multiple Myeloma

Video content above is prompted by the following:

Comment on the recent updates surrounding the management of R/R MM with bispecifics and bispecific combination therapies:

• MonumenTAL-2 for talquetamab (Schinke CD et al. ASCO 2023 Abstract 8036)
• Long-term follow-up from the phase 1/2 MajesTEC-1 for teclistamab (Garfall et al. ASCO 2024 Abstract 7540)
• MagnetisMM-3for elranatamab in R/R MM (Lesokhin A, Nature 2023)

Recent Videos